Drug – bio-affecting and body treating compositions – Identification or warning feature – Taste or smell or chemical irritation to the eye – nose – or...
Patent
1991-01-11
1992-06-02
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Identification or warning feature
Taste or smell or chemical irritation to the eye, nose, or...
514 11, 514549, 514560, 514885, A61K 4900, A61K 3700, A61K 3122, A61K 3120
Patent
active
051184931
ABSTRACT:
Compositions comprising cyclosporine in combination with a vehicle comprising a fatty acid component comprising a fatty acid of the omega-3 or a pharmacologically acceptable salt thereof. Methods for mediating the nephrotoxic effect of cyclosporine and for reducing cyclosporine induced renal prostaglandins comprising administering said cyclosporine in combination with said fatty acid component or a pharmacologically acceptable salt thereof. Eicosapentaenoic acid and docosahexanoic acid are preferred omega-3 fatty acids of the present invention. The compositions and methods of the present invention are useful in clinical and preclinical therapeutic cyclosporine treatment of animals, including humans.
REFERENCES:
patent: 4388307 (1983-06-01), Cavanak
Kelley et al., "A Fish Oil Diet Rich in Eicosapentaenoic Acid Reduces Cyclooxygenase Metabolites, and Suppresses Lupus in MRL-lpr Mice", Journal of Immunology, vol. 134, No. 3, Mar. 1985.
Perico et al., "Functional Signifigance of Exaggerated Renal Thromboxane A.sub.2 Synthesis Induced by Cyclosporin A", Instituted for Pharm. Research .COPYRGT.1986, 581-586.
Siess et al., "Platelet-Membrane Fatty Acids, Platelet Aggregation and Thromboxane Formation During Mackeral Diet", The Lancet, Mar. 1, 1980, 441-444.
Kelley et al., J. Immunol., 134(3):1914 (1985).
Chem. Abstr. vol. 99(3), 1983:21317t; Prickett et al.
Morley, J., Lymphokines, E. Pick, ed., Academic Press, NY, 4:377 (1981).
Lewis, G. P., Br. Med. Bull., 39:243 (1983).
Dunn, M. J., Renal Endocrinology, M. J. Dunn, ed., Williams & Wilkins, Baltimore, pp. 1-74 (1983).
Harrison's Principles of Internal Medicine, 10th ed., pp. 482-487 (1983).
Kawaguchi et al., Transplantation, 40(2):214 (1985).
Whisler et al., Transplantation, 38(4):377 (1984).
Foegh et al., Transplantation Proc., 16(6):1606 (1984).
Foegh et al., Transplantation Proc., 16(6):1603 (1984).
Khirabadi et al., Transplantation, 39(1):6 (1985).
Willis, A. L., Nutr. Rev., 39:289 (1981).
Dyerberg et al., The Lancet, 1:199 (1980).
Siess et al., The Lancet, 1:441 (1980).
Sanders et al., The Lancet, 1:1189 (1980).
Goodnight et al., Arteriosclerosis, 2:87 (1982).
Garton et al., Biochem. J., 50:517 (1952).
Bang et al., Acta Med. Scan., 192:85 (1972).
Bang et al., Acta Med. Scan., 200:69 (1976).
Dyerberg et al., The Lancet, 2:117 (1978).
Kelley et al., J. Immunol., 134(3):1914 (1985).
Kelley et al., J. Clin. Invest., 77:252 (1986).
Higa et al., Brazilian J. Med. Biol. Res., 18:355 (1981).
Beveridge, T., Prog. Allergy 38:269-292 (1986).
Endres et al., New. Eng. J. Med. 320(5):265-271 (1989).
Stoof, T. J. et al., J. of Internal Medicine 226:437-441 (1989).
van der Heide, J. J. et al., Transplantation 49:3:523-527 (1990).
Berthoux, F. et al., Nephrol. Dialy. Transpl. 5:745 (1991) (Abstract).
Brouwer, R. M. L. et al., Kidney International 40:342-348 (1991) (Abstract).
Bennett William M.
Kelley Vicki E.
Brigham and Women's Hospital
Henley III Raymond J.
Oregon Health & Sciences University
Waddell Frederick E.
LandOfFree
Composition having reduced nephrotoxocity comprising a fatty aci does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition having reduced nephrotoxocity comprising a fatty aci, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition having reduced nephrotoxocity comprising a fatty aci will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2227124